DRÄGERWERK AG & CO. KGAA Financials Drägerwerk AG & Co. KGaA London S.E.
Equities
0K5E
DE0005550636
Advanced Medical Equipment & Technology
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 49.3 EUR | +0.25% |
|
-1.01% | -6.87% |
| 06-20 | Warburg Research raises target for Drägerwerk to 64 euros - 'Buy' | DP |
| 06-20 | DRAEGERWERK : Warburg Research gives a Buy rating | ZD |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 823 | 1,141 | 1,020 | 723.3 | 899.6 | 887.2 | - | - |
| Enterprise Value (EV) 1 | 911.7 | 1,328 | 995.9 | 982.5 | 1,097 | 958.6 | 1,064 | 789.5 |
| P/E ratio | 38.7 x | 6.13 x | 7.68 x | -12.2 x | 8.84 x | 10.1 x | 8.58 x | 7.11 x |
| Yield | 0.34% | 0.3% | 0.34% | 0.46% | 3.36% | 3.08% | 2.99% | 4.1% |
| Capitalization / Revenue | 0.3 x | 0.33 x | 0.31 x | 0.24 x | 0.27 x | 0.26 x | 0.24 x | 0.24 x |
| EV / Revenue | 0.33 x | 0.39 x | 0.3 x | 0.32 x | 0.33 x | 0.28 x | 0.29 x | 0.21 x |
| EV / EBITDA | 4.7 x | 2.55 x | 2.37 x | 17.6 x | 3.48 x | 3.05 x | 3.13 x | 2.02 x |
| EV / FCF | 8.9 x | 3.85 x | 3.63 x | -9.15 x | 8.97 x | 8.53 x | 8.49 x | 4.97 x |
| FCF Yield | 11.2% | 26% | 27.6% | -10.9% | 11.1% | 11.7% | 11.8% | 20.1% |
| Price to Book | 0.92 x | - | 0.82 x | 0.59 x | 0.69 x | 0.63 x | 0.6 x | 0.57 x |
| Nbr of stocks (in thousands) | 17,712 | 18,655 | 18,671 | 18,651 | 18,760 | 18,760 | - | - |
| Reference price 2 | 55.70 | 62.80 | 55.25 | 41.75 | 51.80 | 49.05 | 49.05 | 49.05 |
| Announcement Date | 3/5/20 | 3/4/21 | 3/3/22 | 3/16/23 | 3/7/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,781 | 3,406 | 3,328 | 3,045 | 3,374 | 3,477 | 3,628 | 3,754 |
| EBITDA 1 | 193.8 | 521 | 421 | 55.8 | 315 | 314.2 | 340.1 | 391.4 |
| EBIT 1 | 66.58 | 396.6 | 271.7 | -88.61 | 166.4 | 161 | 182.1 | 228.2 |
| Operating Margin | 2.39% | 11.64% | 8.16% | -2.91% | 4.93% | 4.63% | 5.02% | 6.08% |
| Earnings before Tax (EBT) 1 | 49.53 | 360.2 | 236.6 | -102.4 | 141.3 | 134.3 | 157.4 | 188.3 |
| Net income 1 | 33.35 | 250.2 | 154.2 | -64.56 | 110.4 | 91.2 | 107.3 | 129.3 |
| Net margin | 1.2% | 7.34% | 4.63% | -2.12% | 3.27% | 2.62% | 2.96% | 3.44% |
| EPS 2 | 1.440 | 10.25 | 7.190 | -3.410 | 5.860 | 4.867 | 5.717 | 6.895 |
| Free Cash Flow 1 | 102.4 | 345 | 274.5 | -107.4 | 122.3 | 112.4 | 125.4 | 158.8 |
| FCF margin | 3.68% | 10.13% | 8.25% | -3.53% | 3.63% | 3.23% | 3.46% | 4.23% |
| FCF Conversion (EBITDA) | 52.84% | 66.23% | 65.21% | - | 38.83% | 35.77% | 36.88% | 40.59% |
| FCF Conversion (Net income) | 307.05% | 137.93% | 178.01% | - | 110.75% | 123.25% | 116.94% | 122.85% |
| Dividend per Share 2 | 0.1900 | 0.1900 | 0.1900 | 0.1900 | 1.740 | 1.510 | 1.467 | 2.010 |
| Announcement Date | 3/5/20 | 3/4/21 | 3/3/22 | 3/16/23 | 3/7/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2021 S1 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2024 Q1 | 2024 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,428 | 1,633 | 649.5 | 652.9 | 1,302 | - | 761.1 | 771.3 | 1,532 | 788.5 | 735.8 | 768.4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 101.6 | 209.2 | - | -76.61 | -111.7 | - | - | - | - | - | - | 28.3 |
| Operating Margin | 7.11% | 12.81% | - | -11.73% | -8.58% | - | - | - | - | - | - | 3.68% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | -26.91 | - | - | - | 17.04 | 10.72 | 27.75 | - | 7.082 | - |
| Net margin | - | - | -4.14% | - | - | - | 2.24% | 1.39% | 1.81% | - | 0.96% | - |
| EPS | - | - | - | - | - | -1.860 | - | 0.5700 | 1.470 | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/13/20 | 7/29/21 | 4/28/22 | 7/28/22 | 7/28/22 | 10/27/22 | 4/28/23 | 7/27/23 | 7/27/23 | 11/2/23 | 4/25/24 | - |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 88.7 | 187 | - | 259 | 198 | 71.4 | 177 | - |
| Net Cash position 1 | - | - | 24 | - | - | - | - | 97.7 |
| Leverage (Debt/EBITDA) | 0.4577 x | 0.3591 x | - | 4.645 x | 0.6276 x | 0.2272 x | 0.5211 x | - |
| Free Cash Flow 1 | 102 | 345 | 275 | -107 | 122 | 112 | 125 | 159 |
| ROE (net income / shareholders' equity) | 3.1% | 23.7% | 13.5% | -5.01% | 8.11% | 6.23% | 6.93% | 7.9% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 60.50 | - | 67.20 | 70.30 | 75.00 | 78.00 | 81.70 | 85.70 |
| Cash Flow per Share | 7.080 | - | - | - | - | - | - | - |
| Capex 1 | 58.5 | 115 | 110 | - | 68.2 | 83 | 87 | 88.5 |
| Capex / Sales | 2.1% | 3.37% | 3.32% | - | 2.02% | 2.39% | 2.4% | 2.36% |
| Announcement Date | 3/5/20 | 3/4/21 | 3/3/22 | 3/16/23 | 3/7/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
49.05
EUR
Average target price
58
EUR
Spread / Average Target
+18.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.85% | 212B | |
| +9.86% | 188B | |
| +31.11% | 157B | |
| +34.08% | 114B | |
| +3.42% | 64.01B | |
| +19.45% | 54.88B | |
| +1.63% | 48.83B | |
| -3.12% | 39.3B | |
| +1.93% | 35.97B |
- Stock Market
- Equities
- DRW3 Stock
- 0K5E Stock
- Financials Drägerwerk AG & Co. KGaA
